Anti-Obesity Drug Discovery and Development, Volume 1
Atta-ur- Rahman, M. Iqbal Choudhary
Bentham Science Publishers, Jan 1, 2011 - Medical - 283 pages
Obesity is a complex health problem, caused by a number of factors such as excessive food intake, lack of physical activity, genetic predisposition, endocrine disorders, medications and psychiatric illnesses. Onset of obesity in both the developing and the developed world has reached epidemic proportions. In response to this, efforts to control and treat obesity have also been vigorously pursued, ranging from raising awareness about lifestyle changes to the discovery and development of safe and effective anti-obesity drugs.
Anti-obesity Drug Discovery and Development is focused on this very important area of healthcare research. Fifteen well written reviews make this special volume an excellent compilation of recent developments in anti-obesity treatment. the reviews cover a variety of topics including the development of specific, safe and effective receptor antagonists, the role of epithelial endocrine cells and post operative treatment strategies. This book should be useful to clinicians and medicinal chemists involved in ant-obesity research and therapy.
What people are saying - Write a review
We haven't found any reviews in the usual places.
absorption activity adipocytes adiponectin adipose tissue adults agonist anti-obesity drugs apoAI associated atherosclerosis bariatric surgery Biol Blood body fat body weight cannabinoid receptor cardiovascular disease CB1 receptor cells CETP Chem cholesterol clinical compounds coronary cytokines decrease diet dietary dose dyslipidemia effects Endocrinol Metab endogenous endothelial energy expenditure fatty acid food intake function genetic ghrelin glucose HDL levels HDL-C Health hepatic hormone receptor human hypertension increased inflammation inflammatory inhibition inhibitor insulin resistance interaction leptin lipase lipid liver MCH-R1 antagonists mechanisms melanin-concentrating hormone metabolic syndrome mice molecule nesfatin-1 obese patients obesity obestatin opioid oral orlistat overweight and obesity oxidation pathways peptide peripheral Pharmacol pharmacological Physiol placebo plasma potential prevalence of obesity protein rats reduced regulation rimonabant risk factors rodents role sibutramine signaling stimulates studies target therapy treatment of obesity trial triglycerides type 2 diabetes vitamin weight gain weight loss